SeaCrest Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,118 shares of the company’s stock, valued at approximately $324,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Exane Derivatives bought a new position in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $571,000. Korea Investment CORP boosted its stake in Teva Pharmaceutical Industries by 14.3% during the 3rd quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock worth $4,308,000 after acquiring an additional 30,674 shares during the last quarter. Private Capital Management Inc. boosted its stake in Teva Pharmaceutical Industries by 51.3% during the 3rd quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock worth $459,000 after acquiring an additional 8,850 shares during the last quarter. Financial Counselors Inc. boosted its stake in Teva Pharmaceutical Industries by 28.8% during the 3rd quarter. Financial Counselors Inc. now owns 181,130 shares of the company’s stock worth $3,188,000 after acquiring an additional 40,531 shares during the last quarter. Finally, Lockheed Martin Investment Management Co. bought a new position in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $317,000. 51.99% of the stock is currently owned by institutional investors and hedge funds.
Shares of Teva Pharmaceutical Industries Ltd (TEVA) opened at $18.64 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $10.85 and a fifty-two week high of $37.94. The stock has a market cap of $21,183.60, a P/E ratio of 4.82, a PEG ratio of 1.51 and a beta of 0.60.
Several research analysts recently weighed in on the stock. Maxim Group reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday. Cantor Fitzgerald set a $18.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday. BTIG Research downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 target price on the stock. in a report on Friday, February 2nd. Finally, Piper Jaffray Companies set a $16.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday, December 14th. Nine research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $21.54.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/02/09/seacrest-wealth-management-llc-acquires-shares-of-17118-teva-pharmaceutical-industries-ltd-teva.html.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.